FBIO
Fortress Biotech, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.81 | $2.48 | +37% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $1.65 | $2.48 | +50% |
| Two Sigma Investments | Q1 2025(8Q snapshot) | 5Q | $1.71 | $2.48 | +45% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q1 2025 | → $1.71 | -6% |
| Elliott Management | Q3 2015 | Q1 2017 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Fortress Biotech, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 1, 2026 — the most recent Form 4 on file — not from today.
- Form 40001930732-26-000002Apr 1, 2026
- Form 40000941841-26-000002Mar 20, 2026
- Form 40001038977-26-000002Mar 20, 2026
- Form 40001429260-26-000004Jan 6, 2026
- Form 40001647971-26-000002Jan 5, 2026
- Form 40001529687-26-000002Jan 5, 2026
- Form 40001772558-26-000002Jan 5, 2026
- Form 40001429260-26-000002Jan 5, 2026
- Form 40001294517-26-000002Jan 5, 2026
- Form 40001172659-26-000002Jan 5, 2026
- Form 40001930732-25-000004Oct 2, 2025
- Form 40001429260-25-000004Oct 1, 2025
- Form 40001415889-25-015470Jun 3, 2025
- Form 40001415889-25-009620Apr 2, 2025
- Form 40001415889-25-009621Apr 2, 2025
Fundamentals
XBRL · Fortress Biotech, Inc.Annual figures sourced directly from Fortress Biotech, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Fortress Biotech, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 14, 2026
- 8-KMaterial eventMay 14, 2026
- DEF 14AProxy statementApr 28, 2026
- 10-KAnnual reportMar 31, 2026
- 8-KMaterial eventMar 31, 2026
- 8-KMaterial eventMar 30, 2026
- 8-KMaterial eventFeb 23, 2026
- 8-KMaterial eventJan 13, 2026
- S-1FORM S-1Dec 16, 2025
- 8-KMaterial eventDec 15, 2025
- 8-KMaterial eventDec 15, 2025
- 8-KFORM 8-KNov 17, 2025
- 10-QQuarterly reportNov 14, 2025
- 8-KMaterial eventNov 14, 2025
- 8-KMaterial eventOct 1, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $2.41 | $2.48 | +3% |
| Renaissance Technologies | Q4 2025 | open | $2.49 | $2.48 | -0% |
| Two Sigma Investments | Q1 2025 | open | $1.71 | $2.48 | +45% |
| Renaissance Technologies | Q4 2024 | Q3 2025 | $1.65 | $1.93 | +17% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $1.81 | $2.62 | +45% |
| Millennium Management | Q3 2024 | Q1 2025 | $1.81 | $1.71 | -6% |
| Elliott Management | Q3 2015 | Q1 2017 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.